If you or a loved one suffered from any of these Actos Side Effect, you may be entitled to receive compensation for your injuries. Hundreds of Actos side effect victims have already filed Actos lawsuits against Takeda Pharmaceuticals for allegedly failing to warn of serious Actos injuries. The Actos lawyers at Parker Waichman are offering free lawsuit evaluations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you would like to discuss filing an Actos lawsuit with one of the Actos lawyers at Parker Waichman, please contact us today.
Actos, the best selling type 2 diabetes drug in the world, has been linked to a number of dangerous Actos Side Effect, including:
- Bladder Cancer
- Heart Problems (heart attack, congestive heart failure and stroke)
- Eye Injuries (macular edema, cataracts)
What is Actos?
Actos, known generically as pioglitazone hydrochloride, was brought to market in 1999, and quickly became the best selling type 2 diabetes drug in the world. Actos belongs to a class of drugs known as thiazolidinediones, and is used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. It may be used alone or with other medicines, including insulin and metformin.
Pioglitazone hydrochloride, the active ingredient in Actos, is found in a number of other drugs, including:
- Actoplus Met (pioglitazone/metformin)
- Actoplus Met XR (pioglitazone/metformin extended-release)
- Duetact (pioglitazone/glimepiride)
In 2012, the U.S. Food & Drug Administration (FDA) approved the first generic versions of Actos. However, Consumer Reports has advised that type 2 diabetes patients avoid pioglitazone, citing its association with heart problems, bladder cancer, eye injuries and other side effects.
Actos Side Effect
Since its 1999 approval by the FDA, Actos has been associated with a number of serious side effects, some of which can be life-threatening. These potential Actos side effects include:
Actos Bladder Cancer: In June 2011, the FDA warned that long-term use of Actos was associated with an increased risk of bladder cancer. New warnings about the Actos bladder cancer risk were added to the “Warnings and Precautions” section of the Actos label. Regulators in Germany and France suspended sales of Actos that same month because of its association with bladder cancer. Takeda issued an Actos recall in France later that summer.
Actos Heart Problems: Research has linked Actos and other thiazolidinediones with an increased risk of heart problems, including heart attacks, strokes and congestive heart failure. In 2010, the FDA placed restrictions on Avandia, another thiazolidinedione, because of its association with heart attacks. However, no such action was taken with Actos, even though some studies have pointed to a similar risk. In 2002, a “black box warning” – the FDA’s strongest safety alert – was added to the label of Actos warning “that it may increase congestive heart failure in patients with pre-existing heart conditions.”
Actos Eye Injuries: In 2012, a study published in the Archives of Internal Medicine reported that thiazolidinediones, including Actos, were associated with an increased risk of diabetic macular edema, a potentially blinding eye disease. Diabetic macular edema sometimes appears for a few days or weeks after cataract surgery.
In 2002, the Department of Health & Human Services’ Division of Drug Marketing, Advertising and Communications (DDMAC) sent a letter to Takeda, noting that after reviewing the company’s Actos promotional material, it determined that the material was in violation of the Federal Food, Drug and Cosmetic Act. Specifically, the department noted that the promotion was misleading in that it omitted key safety information and showed results that have never been demonstrated.